Novel SA53 MDM2 Inhibitor Therapy Has Potential to be a Breakthrough in Genetically-Targeted Cancer Treatment (CLEVELAND, OH) – Lamassu Biotech, a clinical-stage pharmaceutical company, today announced a significant clinical milestone...
Tag: News
A new type of cancer drug could transform the treatment for many deadly cancers, especially those that have advanced or metastasized and do not respond to other therapies. Rather than...
A partnership with the Cleveland Clinic has prompted a four-year-old biotech startup to relocate its headquarters to Cleveland from Durham, NC, one of the points of the Research Triangle. However, Lamassu...